Progressive Upregulation of Oxidative Metabolism Facilitates Plasmablast Differentiation to a T-Independent Antigen

Graphical Abstract

Highlights
- Activated B cells are poised to increase oxidative phosphorylation
- Plasmablasts require oxidative metabolism to sustain antibody secretion
- Proliferation alone is unable to fully induce oxidative phosphorylation in B cells
- Expression of Blimp1 is required for maximal metabolic activity

Authors
Madeline J. Price, Dillon G. Patterson, Christopher D. Scharer, Jeremy M. Boss

Correspondence
jmbose@emory.edu

In Brief
Price et al. identify a metabolic switch in B cells that is required for maximal antibody secretion. Proliferating, activated B cells switch from glycolysis to oxidative phosphorylation as they differentiate into plasmablasts.

Price et al., 2018, Cell Reports 23, 3152–3159
June 12, 2018 © 2018 The Author(s).
https://doi.org/10.1016/j.celrep.2018.05.053
Progressive Upregulation of Oxidative Metabolism Facilitates Plasmablast Differentiation to a T-Independent Antigen

Madeline J. Price, Dillon G. Patterson, Christopher D. Scharer, and Jeremy M. Boss

1Department of Microbiology and Immunology and the Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA
2Lead Contact
3Correspondence: jmboss@emory.edu

https://doi.org/10.1016/j.celrep.2018.05.053

SUMMARY

Transitioning from a metabolically quiescent naïve B cell to an antibody-secreting plasmablast requires division-dependent cellular differentiation. Though cell division demands significant ATP and metabolites, the metabolic processes used for ATP synthesis during plasmablast formation are not well described. Here, the metabolic requirements for plasmablast formation were determined. Following T-independent stimulation with lipopolysaccharide, B cells increased expression of the oxidative phosphorylation machinery in a stepwise manner. Such activated B cells have increased capacity to perform oxidative phosphorylation but showed dependency on glycolysis. Plasmablasts displayed higher oxidative metabolism to support antibody secretion, as inhibiting oxidative ATP production resulted in decreased antibody titers. Differentiation by Blimp1 was required for this increase in oxidative metabolism, as Blimp1-deficient cells proliferate but do not upregulate oxidative phosphorylation. Together, these findings identify a shift in metabolic pathways as B cells differentiate, as well as the requirement for increased metabolic potential to support antibody production.

INTRODUCTION

Humoral immunity is characterized by the presence of antibody-secreting plasmablasts (PBs), which are derived from the proliferation and differentiation of B cells. B cells undergo significant morphologic and bioenergetic changes to support their transition from quiescent naïve B (nB) cells to PBs, including upregulation of metabolism to support the initial proliferative demands of activated B (actB) cells and, ultimately, the translational demands of PBs (Aronov and Tirosh, 2016; Dufort et al., 2007). For example, following B cell receptor stimulation, actB cells upregulate the expression of Glut1, a cell-surface glucose transporter. Glycolysis and oxidative phosphorylation (OXPHOS) are both increased upon B cell receptor and Toll-like receptor (TLR) stimulation (Caro-Maldonado et al., 2014; Doughty et al., 2006; Woodland et al., 2005). The kinetics of metabolic upregulation that nB cells undergo during the process of differentiation to PB have not been characterized.

Studies in T cell metabolism identified metabolic changes that facilitate differentiation to effector or memory cells (Chang et al., 2013; Fox et al., 2005). In long-lived plasma cells, metabolic differences, including the import of pyruvate into the mitochondria, occur and are believed to aid in their long-term survival (Lam et al., 2016). Though metabolic demands change as immune cells become activated and acquire distinct functions, the metabolic changes associated with cell division versus differentiation remain to be defined.

Here, we report a progressive increase in the expression of genes associated with primary metabolic functions during the initial proliferative stage as B cells differentiate. We find that increased metabolic demand is driven, first, by cellular division and, later, by differentiation. Furthermore, we find that expression of the master regulator of PB differentiation, Blimp1, was required for maximal metabolic activity. These data, therefore, link the B cell transcriptional and differentiation programs to increased metabolic capacity of PB, allowing these cells to execute their function.

RESULTS

Metabolism Changes Correspond with Differentiation State

To determine whether metabolic pathways were regulated at the level of gene expression, previously collected gene expression data (Barwick et al., 2016) during B cell differentiation was reanalyzed. In those experiments, cell-trace-violet (CTV)-labeled nB cells were transferred to B cell-deficient μMT mice and challenged with TLR4 agonist, lipopolysaccharide (LPS). After 3 days, the transferred splenic cells were sorted based on their cell division status, and the transcriptomes of cells representing the early (divisions 0, 1, and 3), middle (divisions 5 and 8−) and late (division 8+) stages of differentiation were determined. Divisions 8− and 8+ signify the CD138 status (−/+) of cells that have undergone at least 8 divisions. Division 8+ cells have the characteristics of PBs (Barwick et al., 2016; Smith et al., 1996). This analysis showed a stepwise upregulation of genes involved in both the tricarboxylic acid (TCA) cycle (Figures 1A and 1B) and the electron transport chain (ETC) (Figure 1C), the two components of OXPHOS. Six TCA genes were upregulated as the cells progressed through their divisions to PBs, including Sdhb, Sdhd, Sdha, Sdhe, and Pahb. The most upregulated TCA gene, Sdhb,
encodes succinate dehydrogenase subunit B, which oxidizes succinate to fumarate. The succinate dehydrogenase complex also participates in the ETC by reducing ubiquinone (Guzy et al., 2008), thereby bridging the TCA cycle and the ETC.

At least 30 ETC genes were also upregulated as B cells progressed to PBs, including *Atp5g2*, *Atp5h*, *Atp5e*, *Atp5o*, and *Uqcr10* (Figure 1C). The most upregulated gene, *Atp5g2*, encodes a subunit of the mitochondrial ATP synthase complex (complex V), which catalyzes ADP to ATP using the proton gradient established by ETC complexes I–IV. Importantly, inhibition of complex V by oligomycin allows for analysis of the contribution of ATP synthase to OXPHOS (discussed later).
Gene set enrichment analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005) was used to assess transcript expression changes in metabolic pathways. Comparing each division after LPS stimulation to undivided cells suggested that the OXPHOS pathway was significantly upregulated in a stepwise manner (Figure 1D). Conversely, the GSEA signature for glycolysis failed to reach significant enrichment in any of the divisions.

Examples of OXPHOS genes that displayed progressive upregulation included Sdhb, Atp5g2, Cs, Cox7a2, and Sod1 with the largest changes occurring at division 8+ (Figure 1E). Cs encodes citrate synthase, which catalyzes acetyl-coenzyme A (CoA) from citrate and is the first step of the TCA cycle. Cox7a2 codes for cytochrome c oxidase, which is the final component of the ETC before ATP synthase and catalyzes electron transfer from cytochrome c to oxygen. Sod1 encodes superoxide dismutase 1 that catalyzes the reduction of oxygen radicals in the cytoplasm (McCord and Fridovich, 1969). Thus, the transcriptome is reprogrammed to support changes in metabolic machinery between nB cells and PBs.

**T-Independent B Cell Activation Increases OXPHOS Ex Vivo**

To determine whether gene expression and functional metabolic changes correlate, an ex vivo model of B cell stimulation induced by TLR4 ligation (Yoon et al., 2012) was used. After 2 days of ex vivo LPS stimulation, cells had undergone up to 4 divisions, and ~15% of B cells upregulated expression of CD138 (Figure 2A). By 3 days, cells had undergone 4–6 divisions, and the number of CD138+ cells increased by about 27%. At 2 days, there was a modest, statistically significant increase in OXPHOS, as measured by oxygen consumption rate (OCR), between LPS-stimulated and nB cells (Figure 2B). By 3 days, there was nearly a 10-fold increase in OCR (Figure 2B), corresponding to the increase in actB cell and PB frequency (Figure 2A). These data corroborate the gene expression data and demonstrate that use of OXPHOS is increased as B cells progress through differentiation ex vivo.

**PBs Rely on OXPHOS for Antibody Secretion**

Given the aforementioned observation that OXPHOS increased with PB frequency, its functional requirement for antibody synthesis and secretion was determined. Ex-vivo-generated PBs (3 days) were treated with OXPHOS inhibitors or reactive oxygen species (ROS) manipulators, and the levels of secreted immunoglobulin M (IgM) were measured by ELISA (Figure 2C). Treatment with the ATP synthase inhibitor oligomycin (Franchi et al., 2017) resulted in a highly significant 1.5-fold decrease in antibody concentration. Other inhibitors of OXPHOS, including FCCP, antimycin A, and rotenone + antimycin A, caused similar decreases in antibody concentration (Figure 2C) without any increase in cell death (data not shown). Rotenone, a complex I inhibitor, oxidizes NADH to NAD+, which allows the ETC to progress. In the process, complex I also generates ROS (Murphy, 2009). Interestingly, neither rotenone, N-acetyl-L-cysteine (an ROS inhibitor), nor pyocyanin (an ROS inducer) impacted antibody titers (Mascielli and Sitia, 2008). ROS were measured and found to be higher in PBs compared to actB and nB cells (Figure 2D). Likewise, superoxide species were increased upon activation but comparable between actB cells and PBs. However, because
ROS inducers and inhibitors had no impact on antibody secretion, we conclude that oxidative metabolism, but not ROS, is required for maximal antibody titers.

Reduced antibody titers did not distinguish between defects in antibody production or secretion. Intracellular IgM staining and analysis by flow cytometry showed that PBs produced similar levels of IgM, regardless of oligomycin or vehicle treatment (Figure 2E). Therefore, oligomycin interferes with PB antibody secretion but not the production of IgM.

**Differentiating B Cell Subsets Increase Oxygen Consumption in a Stepwise Manner**

To track the activation and differentiation state of B cells in vivo, two phenotypic markers were used. Activation was defined by surface expression of the sialic-acid-binding protein GL7 (Naito et al., 2007). As mentioned earlier, as B cells divide and ultimately differentiate to PBs, they acquire expression of CD138. In an in vivo LPS stimulation assay (Yoon et al., 2012), ~15 and 30% of the cells expressed CD138 and GL7, respectively (Figure 3A). To characterize the metabolic changes occurring at distinct phenotypic stages throughout differentiation, nB cells (GL7−CD138−), actB cells (GL7+CD138−), and PBs (CD138+) were purified by magnetic enrichment (Figure 3B), normalized to the same cell number, and their use of OXPHOS was determined. Quiescent nB cells showed minimal responses to mitochondrial stressors (Figure 3C), indicating no significant use of OXPHOS. Compared to nB cells and PBs, actB cells exhibited intermediate levels of basal respiration (Figures 3C and 3D); and, upon uncoupling of the ETC with FCCP, their maximal OCR was also intermediate (Figure 3E). PBs displayed the highest level of OXPHOS usage; and their spare respiratory capacity (SRC), the difference between maximal and basal respiration or reserved oxidative ability, was highest among the cell types (Figure 3F). The intermediate OXPHOS levels in actB cells may indicate a transitional step in their metabolic programming.

**OXPHOS Increases PB Frequency**

To test whether promoting OXPHOS would result in increased PB differentiation, nB cells were treated with dichloroacetate, stimulated with LPS, interleukin (IL)-2, and IL-5 ex vivo for 3 days, and the frequency of CD138+ PBs was measured by flow cytometry. Dichloroacetate inhibits pyruvate dehydrogenase kinase, promoting OXPHOS at the expense of glycolysis (Sanchez et al., 2013; Shen et al., 2013; Stockwin et al., 2010). Dichloroacetate treatment increased the total frequency of CD138+ plasmablasts and the frequency per cell division (Figure 3G). Dichloroacetate-treated cultures did not divide as extensively as vehicle-treated cultures, supporting a role for OXPHOS in differentiation of plasmablasts, but not in cell division.

**actB Cells and PBs Contain Similar Amounts of ATP**

Differences in oxygen consumption between actB cells and PBs suggest that these cells may contain different amounts of ATP. Surprisingly, quantification of ATP levels in cell extracts showed that actB cells and PBs retain similar concentrations of ATP (Figure 3G). Additionally, after oligomycin treatment, ATP levels in actB cells and PBs were decreased, indicating that both cell types were sensitive to mitochondrial ATP synthase inhibition (Figure 3G). nB cells similarly showed a small but significant decrease with oligomycin treatment. Together, this suggests that rapidly proliferating actB cells use other metabolic pathways to augment their ATP production (Lunt and Vander Heiden, 2011).

**actB Cells Use Glycolysis to Supplement Their Metabolism**

A glycolytic rate assay that measures glycolysis in the absence of OXPHOS was performed on the cell subsets. nB and actB cells were unresponsive to inhibition of OXPHOS, suggesting that, although these cells use OXPHOS, they were not reliant on this pathway (Figure 3H). PBs showed a compensatory increase in proton extrusion rate (PER), corroborating the results shown previously that PBs use significant OXPHOS. The specific contribution of glycolysis to PER was calculated by subtracting total PER from the CO2-derived PER produced from OXPHOS. ActB cells had a higher percentage of PER from glycolysis than both nB cells and PBs, suggesting their use of this pathway (Figure 3H).

**Blimp1-cKO B Cells Fail to Upregulate OXPHOS**

As nB cells differentiate to PBs, they first become activated, proliferate, and subsequently differentiate. To determine whether metabolic changes are due to proliferation or differentiation, a Prdm1<sup>fl/fl</sup> Cd19<sup>Cre-/+</sup> (Blimp1-cKO) mouse model was used, which does not form PBs (Shapiro-Shelef et al., 2003). To track proliferation and differentiation in vivo, Blimp1-cKO or wild-type (WT) B cells were labeled with CTV and adoptively transferred into congenically marked μMT mice. Mice receiving WT or Blimp1-cKO splenocytes reconstituted to a similar degree (Figure 4A) and similarly expressed GL7 (Figure 4B). Cell division analysis showed that the cells divided normally (Figures 4C and 4D), suggesting that there is no in vivo proliferation defect caused by Blimp1 deficiency. As anticipated from the model, whereas WT B cells upregulated expression of CD138 at division 8, Blimp1-cKO cells fail to do so (Figures 4C and 4D). WT nB cells, actB cells, and PBs as well as Blimp1-cKO actB cells were magnetically enriched and tested for their use of OXPHOS. The OCR between WT and Blimp1-cKO actB cells was identical (Figure 4E) and less than that for PBs, suggesting that, despite having similar proliferation profiles, the generation of PBs and the ability for cells to reach their full metabolic capacity are concomitant. Thus, these data suggest that the Blimp1 transcriptional program is required to support the increased metabolic requirements of PBs.

**DISCUSSION**

The balance between catabolism and anabolism must meet the demands of the cell type and the environment. These needs can be met by various metabolic pathways, including OXPHOS, glycolysis, and fatty acid oxidation, all of which exist in any given cell. Here, we provide evidence for a specific and ordered upregulation of the OXPHOS program during B cell differentiation in response to a T-independent antigen. This program ultimately allows PBs to utilize the OXPHOS machinery to its maximal extent,
Figure 3. B Cells Progressively Upregulate OXPHOS after LPS Stimulation In Vivo

(A) Flow cytometry plot for nB cells (B220), actB cells (GL7), and PBs (CD138) from spleens of mice inoculated with LPS intravenously (i.v.) (left). Summary data of cell frequencies (right). Data are indicated as mean ± SD and represent three groups of 3 mice each.

(B) Representative flow cytometry plots of nB cells from PBS-treated mice and actB cells and PBs from LPS-treated mice following magnetic enrichment. Purity frequencies are indicated. Data are representative of 3 groups each containing 3 control and 4–5 LPS-treated mice.

(C) Enriched subsets from (B) were analyzed by mitochondrial stress test as in Figure 2B. Data represent mean ± SD of one group of three; each group contained 3 control and 4–5 LPS-treated mice. *p ≤ 0.0001.

(D) Summary data from (C) showing basal OCR (final time point prior to oligomycin), mean ± SD.

(E) Summary data from (C) showing maximal OCR (first time point following FCCP), mean ± SD.

(F) Summary data from (C) showing spare respiratory capacity (maximal – basal), mean ± SD.

(G) Representative flow cytometry plots of naive B cells cultured with vehicle or 10 mM dichloroacetate (DCA). Total frequency of CD138+ PBs and frequency per division are plotted at the right. Data are representative of mean ± SD of two experiments with 3 mice each.

(H) ATP concentration was determined from FACS-isolated cell populations, as described in the Experimental Procedures, with or without oligomycin. Purity of these populations was >95% (data not shown). Data represent mean ± SD of 2 groups each of 2 control and 5 LPS-treated mice.

(I) GL7+ and CD138+ positively selected B cells were analyzed by glycolytic rate assay. % PER from glycolysis was calculated as (basal glycolysis)/(basal PER) × 100%. Data are indicated as mean ± SD and represent one group of two, each containing 3 control and 5 LPS-treated mice. *p ≤ 0.01.
reflecting the high demand for ATP in antibody synthesis and secretion.

As B cells divide during in vivo differentiation to LPS, changes in metabolic programming occurred first at the level of transcription where 132 genes encoding proteins associated with both the TCA cycle and ETC were progressively increased. Succinate dehydrogenase subunits A through D were upregulated during early and late divisions, as cells progressed to PBs. In addition to converting succinate to fumarate in the TCA cycle; succinate dehydrogenase reduces ubiquinone to ubiquinol in complex II of the ETC. This enzymatic step facilitates the transfer of electrons from complex II to complex III; as such, succinate dehydrogenase aids in both the proton pump/gradient and in the transfer of electrons to the ATP synthase. In macrophages, Sdhb is important for expression of hypoxia inducible factor 1 alpha (HIF-1α) and IL-1β (Mills et al., 2016). Additionally, succinate is the downstream metabolite of the α-ketoglutarate (αKG) dehydrogenase complex. A high ratio of αKG to succinate has been shown to promote differentiation of M2 macrophages (Liu et al., 2017). However, the role of succinate and/or succinate dehydrogenase has not been identified in circulating PBs.

Previous reports showed that 2 days after LPS stimulation ex vivo, Blimp1-cKO B cells had a slight proliferative advantage over WT cells (Shapiro-Shelef et al., 2003). Our ex vivo data showed similar results 3 days following LPS stimulation (data not shown). However, in response to LPS in vivo, Blimp1-cKO B cells proliferated at the same rate as WT B cells, and there were no significant differences in cell numbers at any division.
The differences between in vivo and ex vivo stimulation could be attributed to cytokines or factors not present or overrepresented in an ex vivo culture system. Nonetheless, the Blimp1-cKO defect observed here and previously (Shapiro-Shelef et al., 2003) was due to a block in differentiation, as measured by the failure to upregulate CD138.

PB differentiation occurs with concomitant morphological changes to support robust antibody secretion, including significant growth of the endoplasmic reticulum (ER). High levels of antibody production result in a stress response that is tempered by upregulation of the unfolded protein response (UPR) (Reimold et al., 2001). The UPR is increased upon recognition of misfolded proteins in the ER, which is usually associated with hypoxia, low glucose, or calcium imbalance. XBP-1, a transcription factor induced by the UPR in PBs (Barwick et al., 2016), is required for differentiation (Iwakoshi et al., 2003), as well as mitochondrial mass and function (Jang et al., 2015; Shaffer et al., 2004). This suggests a direct link between antibody secretion and metabolic reprogramming that we further characterized by identifying a requirement for ATP synthase in IgM secretion, as well as an increased propensity for B cells to differentiate when OXPHOS is induced by dichloroacetate.

Coupled with the transcriptional changes were observations reflecting the utilization of the OXPHOS pathway. OCR in PBs may be sensitive to redox imbalances induced by high levels of OXPHOS and protein translation. However, Sod1 was upregulated in PBs and may temper the redox imbalances. Genes that produce the ATP synthase complex were significantly upregulated in division 8+ PBs, which was consistent with their sensitivity to oligomycin. ActB cells maintained a relatively low OCR that was similar to that of quiescent nB cells. Surprisingly, actB cells contained levels of ATP similar to those for PBs, which had a high OCR. Thus, because ATP levels were the same, an additional pathway was hypothesized to be used in actB cells. Similar to proliferating T cells, proliferating B cells upregulate glycolysis (Chang et al., 2013; Maclver et al., 2013; Michalek et al., 2011). Blimp1-cKO actB cells consumed oxygen to the same degree as WT actB cells, both of which were less than that consumed by PBs, indicating that proliferating B cells rely on glycolysis to supplement their ATP generation. ActB cells exhibited slightly higher OXPHOS than nB cells but have the potential to form PBs and are, therefore, poised to increase OXPHOS to a level similar to that of PBs at the point of differentiation. Thus, B cells are inherently programmed to increase the transcription of OXPHOS pathway genes during differentiation, and this programming is required for maximal antibody secretion.

EXPERIMENTAL PROCEDURES

Detailed procedures for cell isolation, ex vivo differentiation, and the Seahorse Bioanalyzer, and antibody clones can be found in the Supplemental Experimental Procedures.

Mice and LPS Challenge

C57/BL6J mice 8–12 weeks of age were used for experiments, with a mix of male and female mice. Prdm1CreERT2 Cdt1GtgOΔ (Blimp1-cKO) mice were previously generated (Shapiro-Shelef et al., 2003). In vivo LPS challenge was 50 μg LPS (Enzo, ALX-581-008) intravenously. Mice were analyzed 3 days after challenge. All animals were housed by the Emory Division of Animal Resources, and all protocols were approved by the Emory Institutional Animal Care and Use Committee (IACUC).

Flow Cytometry

Cells were washed and resuspended at 10⁶ cells per milliliter in PBs with 1% BSA and 2 mM EDTA. Cells were stained for 1 hr with antibody cocktails (see Supplemental Experimental Procedures) and fixed with 1% paraformaldehyde before analysis. Flow-cytometric analysis was collected on a Becton Dickinson (BD) LSRII, and FCS files were exported using FACSDiva (v6.2). Analysis of flow cytometry data was conducted with FlowJo software (v10).

ATP Quantification

Cells were sorted on a BD FACSrIA II and plated at 50,000 cells per well before vehicle or oligomycin treatment for 2 hr at 37°C. ATP was quantified with use of a standard curve, as per manufacturer’s protocol (Abcam, #113849).

Statistical Analysis

Statistical analyses were performed using a Student’s t test. Paired analyses were used in all in vivo LPS-treatment experiments where actB cells and PBs were isolated from the same animal. In all other cases, a two-tailed t test was used.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures and can be found with this article online at https://doi.org/10.1016/j.celrep.2018.05.053.

ACKNOWLEDGMENTS

We thank Dr. D. Neeld for designing and creating the graphical abstract, R. Butler for animal husbandry and care, A. Kania and R. Haines for comments and critiques of the manuscript, and K. Fife and R. Karaffa for cell sorting at the Emory Flow Cytometry Core. This work was supported by an NIH grant (1R01AI123733) to J.M.B.

AUTHOR CONTRIBUTIONS

M.J.P. designed and performed experiments, analyzed data and wrote the manuscript. D.G.P. performed experiments. C.D.S. performed bioinformatic analyses. J.M.B. designed experiments and wrote the manuscript. All authors edited the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: December 19, 2017
Revised: April 11, 2018
Accepted: May 15, 2018
Published: June 12, 2018

REFERENCES


Supplemental Information

Progressive Upregulation of Oxidative Metabolism Facilitates Plasmablast Differentiation to a T-Independent Antigen

Madeline J. Price, Dillon G. Patterson, Christopher D. Scharer, and Jeremy M. Boss
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

**Cell Isolation**

Splenic cell suspensions were made by mechanically forcing spleens through a 40 µm filter and lysing red blood cells with ACK lysis buffer (0.15 M NH₄Cl, 10 mM KHCO₃, 0.1 mM EDTA) for 3 mins before quenching the reaction with four volumes RPMI 1640 media (Corning Cellgro 50-020-PC) supplemented with 10% heat-inactivated FBS (Sigma-Aldrich), 1% MEM non-essential amino acids (Sigma ENBF3930-01), 100 µM sodium pyruvate (Sigma RNBF6686), 10 mM HEPES (HyClone SH30237), 1x Penicillin-Streptomycin-Glutamine (Gibco 10378016), 0.0035% β-mercaptoethanol (Sigma-Aldrich). Naive B cells were isolated using immunomagnetic negative selection for CD43 (Miltenyi #130-090-862) following the manufacturer's protocol. Purity was confirmed by flow cytometry. Plasmablasts were isolated by staining with CD138-APC (BD, 281-2), and enriching the CD138+ fraction of splenocytes using a positive immunomagnetic enrichment on APC (Miltenyi #130-090-855). Purity greater than 80% CD138+ was used in downstream analyses (Seahorse). GL7+ cells were subsequently enriched from CD138 depleted sample in order to avoid contaminating plasmablasts that are CD138+ and also express GL7. CD138 depleted cells were stained with GL7-PE (Biolegend #144608) then enriched using a positive immunomagnetic enrichment on PE (Miltenyi #130-105-639).

**Flow Cytometry**

Staining panels included anti-Fc (anti-CD16/CD32) (Tonbo Biosciences, 2.4G2), anti-CD11b (Tonbo Biosciences M1/70), anti-CD11c (Tonbo Biosciences N418), anti-F4/80 (Biolegend BM8), and Thy1/2 (Biolegend 30-H12) conjugated to APC-Cy7 each at a concentration of 0.25 µg per 1 × 10⁶ cells to remove dendritic cells, macrophages, and T cells. The following stains and antibody-fluorophore combinations were used to assess cellular phenotype: anti-B220-PerCP-Cy5.5 or -PE-Cy7 (Tonbo Biosciences RA3-6B2) at 0.5 µl per 1 × 10⁶ cells; anti-CD138-APC, or -BV711 (BD, 281-2) at 0.125 µl per 1 × 10⁶ cells; anti-GL7-BV421 or -PE (Biolegend GL7) at 0.25 µl per 1 × 10⁶ cells; Zombie Yellow (BV570) (Biolegend 77168), and CTV (Life Technologies #C34557). CTV was used at 10 µM per 1 × 10⁷ cells/ml. Intracellular IgM staining was performed using the BD Fixation/Permeabilization Kit (554714) using IgM-FITC at 0.25 µl per 10⁵ cells (eBioscience 1-5890-85). Reactive oxygen species and superoxide were measured with ROS/Superoxide Detection Assay (Abcam 139476) as per manufacturer’s protocol. This kit included the inhibitors N-acetyl-L-cysteine and pyocyanin. Staining panels included fluorescence minus one (FMO) controls to ensure that correct compensation and gating were applied.

**Ex vivo differentiation**

B cells were differentiated *ex vivo* as previously described, but with the incorporation of division-tracking dye, Cell Trace Violet (CTV). B cells were isolated using immunomagnetic separation as above, and stained with CTV at a concentration of 20 × 10⁶ cells/ml in PBS. Cells were differentiated at an initial concentration of 0.5 × 10⁶ cells per ml with LPS (20 µg/ml; Sigma #L2630), IL-2 (20 ng/ml; eBioscience #14-8021), and IL-5 (5 ng/ml; eBioscience #14-8051). Half doses of LPS and cytokines were given on subsequent days. Where indicated, dichloroacetate (Sigma 347795) was dissolved in dH₂O and added at 10 mM concentration each day of culture.
Seahorse Bioanalyzer

Cartridge of FluxPack was hydrated at least 12 hours prior to running assay with 200 µl dH₂O in 37°C, non CO₂ incubator. 1 hour prior to assay, dH₂O was removed and 200 µl pre-warmed Seahorse calibrant solution (Agilent 103059-000) was added to wells. Purified cell populations were washed in Seahorse XF Assay media supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine (Sigma G7513), and 5.5 mM glucose for Mitochondrial Stress Test, before adjusting the pH to 7.4 +/- 0.1 at 37°C. For Glycolytic Flux Test, Seahorse XF Base Media without phenol red (Agilent 103335) was supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 5 mM HEPES (HyClone SH30237), and 5.5 mM glucose. Cells were washed 1x in appropriate media and counted by flow cytometry with AccuCheck counting beads (Invitrogen PCB100). CellTak (Corning 354420) was diluted in sterile PBS to a final concentration of 22.4 µg/ml. 25 µl was added per well of Seahorse XFe96 cell culture plate and incubated for 20 mins at room temperature before use. CellTak was washed out with 200 µl dH₂O and then 400,000 cells were plated per well. Cell plate was incubated in 37°C, non CO₂ incubator for 45 minutes prior to running assay. Drugs were diluted in Seahorse prepared media for injection into each port. Port A, Oligomycin (Sigma 75351), was used at a final concentration of 2 µM. Port B, FCCP (Sigma C2920) was used at a final concentration of 2.5 µM. Port C injects a combination of Rotenone (Sigma R8875) and Antimycin A (Sigma A8674), each at a final concentration of 1 µM. 2-DG (D8375) was used at a final concentration of 50 mM for Glycolytic Rate Assay.

Adoptive Transfer

µMT mice were bred to CD45.1+ C57Bl/6 mice to generate CD45.1+ µMT mice. Splenocytes were isolated from CD45.2+ Blimp⁰⁻ Cd19⁰⁻ or Cd19⁺/⁻ mice, labeled with Cell Trace Violet (ThermoFisher C34557) as per manufacturer’s instructions, and injected via tail vein into sex-matched CD45.1+ µMT host mice. 24 hours later, host mice were infected with 50 µg LPS (Salmonella Minnesota R595 Enzo ALX-581-008) via tail vein injection. Mice were analyzed three days following LPS challenge.